Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19520117 | 0.77 | NUDT1 (0.46) | NUDT1PDE3BPDE3AL3MBTL1 | |
| SCHEMBL19772846 | 0.74 | GABRA1 (0.40) | NUDT1L3MBTL1 | |
| SCHEMBL22179462 | 0.73 | TLR7 (0.40) | PDE3BPDE3ATLR7KDM4EUSP2 | |
| SCHEMBL18858530 | 0.73 | PDE3B (0.44) | PDE3BPDE3AKDM4EUSP2HPGD | |
| SCHEMBL9935446 | 0.72 | NUDT1 (0.52) | NUDT1L3MBTL1 | |
| SCHEMBL5408532 | 0.72 | NUDT1 (0.52) | NUDT1L3MBTL1 | |
| SCHEMBL24994891 | 0.69 | SRC (0.33) | NUDT1L3MBTL1TLR7 | |
| SCHEMBL10964015 | 0.68 | PDE3B (0.39) | NUDT1PDE3BPDE3ATLR7KDM4E | |
| SCHEMBL15165105 | 0.68 | NUDT1 (0.46) | NUDT1L3MBTL1 | |
| SCHEMBL27897587 | 0.68 | TTK (0.45) | NUDT1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709468-B2 | Imidazo based heterocycles | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070099925-A1 | Novel imidazo based heterocycles | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099925-A1 | Novel imidazo based heterocycles | CDK4, CDK2, MAP3K19 | NUDT1 1635/4885PDE3B 1862/4885PDE3A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.